Characteristics of CLL study population
| N . | 15, n (%) . |
|---|---|
| Age (y), median (range) | 69 (59-82) |
| Gender | |
| Female | 6 (40) |
| Male | 9 (60) |
| Race | |
| Caucasian | 15 (100) |
| Disease status | |
| Naïve | 2 (13) |
| Frontline active | 2 (13) |
| Relapse active | 3 (20) |
| Relapse in need of treatment | 2 (13) |
| In remission | 5 (33) |
| Previous treatment | |
| <3 | 4 (27) |
| ≥3 | 7 (47) |
| Current treatment | |
| BTK inhibitor (BTKi) | 3 (20) |
| Bcl2 inhibitor (Bcl2i) | 4 (27) |
| Off-therapy | 6 (40) |
| Watch and wait (W&W) | 2 (13) |
| IGHV status | |
| Mutated | 2 (13) |
| Risk factors | |
| Trisomy 12 | 1 (7) |
| 17p deletion/T53 mutation | 5 (33) |
| 11q deletion | 2 (13) |
| Complex karyotype | 2 (13) |
| High βM2 | 2 (13) |
| Serum IgG level (mg/dL), median (range) | 619 (159-1141) |
| Serum IgM level (mg/dL), median (range) | 45 (<5-179) |
| Serum IgA level (mg/dL), median (range) | 98 (10-210) |
| B lymphocytes (%), median (range) | 7.2 (0-84.6) |
| N . | 15, n (%) . |
|---|---|
| Age (y), median (range) | 69 (59-82) |
| Gender | |
| Female | 6 (40) |
| Male | 9 (60) |
| Race | |
| Caucasian | 15 (100) |
| Disease status | |
| Naïve | 2 (13) |
| Frontline active | 2 (13) |
| Relapse active | 3 (20) |
| Relapse in need of treatment | 2 (13) |
| In remission | 5 (33) |
| Previous treatment | |
| <3 | 4 (27) |
| ≥3 | 7 (47) |
| Current treatment | |
| BTK inhibitor (BTKi) | 3 (20) |
| Bcl2 inhibitor (Bcl2i) | 4 (27) |
| Off-therapy | 6 (40) |
| Watch and wait (W&W) | 2 (13) |
| IGHV status | |
| Mutated | 2 (13) |
| Risk factors | |
| Trisomy 12 | 1 (7) |
| 17p deletion/T53 mutation | 5 (33) |
| 11q deletion | 2 (13) |
| Complex karyotype | 2 (13) |
| High βM2 | 2 (13) |
| Serum IgG level (mg/dL), median (range) | 619 (159-1141) |
| Serum IgM level (mg/dL), median (range) | 45 (<5-179) |
| Serum IgA level (mg/dL), median (range) | 98 (10-210) |
| B lymphocytes (%), median (range) | 7.2 (0-84.6) |